Warning: The NCBI web site requires JavaScript to function. more...
Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives.
Ardern-Jones A, Kenen R, Lynch E, Doherty R, Eeles R.
Hered Cancer Clin Pract. 2010 Jan 12;8(1):1.
Related citations
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS.
Oncologist. 1996;1(5):326-330.
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Ardern-Jones A, Kenen R, Eeles R.
Eur J Cancer Care (Engl). 2005 Jul;14(3):272-81.
Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives.
Cypowyj C, Eisinger F, Huiart L, Sobol H, Morin M, Julian-Reynier C.
Psychooncology. 2009 Feb;18(2):209-15.
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.
J Clin Oncol. 2003 May 1;21(9):1675-81.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
Lee E, McKean-Cowdin R, Ma H, Chen Z, Van Den Berg D, Henderson BE, Bernstein L, Ursin G.
Breast Cancer Res. 2008;10(1):R19. Epub 2008 Feb 19.
Testing for hereditary breast and ovarian cancer in the southeastern United States.
Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD.
Ann Surg. 2000 May;231(5):624-34.
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.
JAMA. 2006 Mar 22;295(12):1379-88.
No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
Dorval M, Gauthier G, Maunsell E, Dugas MJ, Rouleau I, Chiquette J, Plante M, Laframboise R, Gaudet M, Bridge PJ, Simard J.
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2862-7.
Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.
Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF.
Am J Med Genet A. 2003 Jun 15;119A(3):266-72.
One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF.
Breast Cancer Res Treat. 2002 May;73(2):97-112.
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
Cancer. 2006 Dec 15;107(12):2745-51.
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.
Br J Cancer. 2009 Jan 27;100(2):421-5. Epub 2008 Dec 16.
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.
Gynecol Oncol. 2005 May;97(2):457-67.
Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Frank TS, Deffenbaugh AM, Hulick M, Gumpper K.
Dis Markers. 1999 Oct;15(1-3):89-92.
Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS, Seminsky M, Honeyford J, Doan B, Franssen E, Meschino W, Chart P, Warner E.
CMAJ. 2001 Apr 3;164(7):1005-9.
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
Hallowell N, Foster C, Ardern-Jones A, Eeles R, Murday V, Watson M.
Genet Test. 2002 Summer;6(2):79-87.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ, Bewtra C.
Fam Cancer. 2004;3(3-4):265-81. Review.
An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
Metcalfe KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA.
J Med Genet. 2000 Nov;37(11):866-74.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on